Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,688,908
  • Shares Outstanding, K 255,558
  • Annual Sales, $ 2,489 M
  • Annual Income, $ 263,480 K
  • 36-Month Beta 1.54
  • Price/Sales 17.78
  • Price/Cash Flow 181.68
  • Price/Book 16.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.72
  • Number of Estimates 8
  • High Estimate 0.82
  • Low Estimate 0.61
  • Prior Year 0.32
  • Growth Rate Est. (year over year) +125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
151.80 +28.26%
on 12/24/18
194.78 -0.04%
on 01/18/19
+31.27 (+19.13%)
since 12/18/18
3-Month
151.80 +28.26%
on 12/24/18
194.78 -0.04%
on 01/18/19
+15.80 (+8.83%)
since 10/18/18
52-Week
144.07 +35.14%
on 06/06/18
194.92 -0.11%
on 10/01/18
+37.51 (+23.86%)
since 01/18/18

Most Recent Stories

More News
Moderna (MRNA) Announces Pipeline Progress, Shares Rise

Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

AZN : 36.55 (+0.72%)
MRK : 75.87 (+0.36%)
VRTX : 194.70 (+2.19%)
MRNA : 16.69 (+2.33%)
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

CRSP : 37.13 (+3.48%)
VRTX : 194.70 (+2.19%)
EDIT : 26.14 (-0.27%)
NTLA : 15.20 (+1.88%)
Vertex Joins Forces With Arbor to Build Gene-Editing Therapies

Vertex (VRTX) inks a collaboration deal with small biotech entity Arbor to discover novel proteins for progressing discovery of gene-editing therapies to tackle serious ailments.

GHDX : 72.70 (+3.05%)
VRTX : 194.70 (+2.19%)
INO : 5.09 (+0.20%)
VNDA : 31.05 (+0.75%)
X-Chem and Vertex Expand Existing Partnership

---- Focus on discovery and development of small-molecule leads against key targets for severe, genetic diseases

VRTX : 194.70 (+2.19%)
CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for...

CRSP : 37.13 (+3.48%)
VRTX : 194.70 (+2.19%)
Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies

---Arbor to receive up-front cash payment and convertible note investment, research funding, and potential for additional milestones and royalty payments-

VRTX : 194.70 (+2.19%)
Vertex to Present at the J.P. Morgan Healthcare Conference on January 7

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. ET...

JPM : 104.59 (+1.62%)
VRTX : 194.70 (+2.19%)
NACD New England Chapter Names Leaders in Corporate Governance as 2019 'Director of the Year' Honorees

Recognizing leadership and transformation, the National Association of Corporate Directors New England Chapter (NACDNE) today announced it is honoring two corporate boards and three individuals...

VRTX : 194.70 (+2.19%)
The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

VRTX : 194.70 (+2.19%)
EVFM : 4.00 (+2.56%)
INCY : 78.42 (-0.32%)
AMGN : 203.88 (+0.97%)
ADRO : 2.70 (-6.25%)
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY

A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.

VRTX : 194.70 (+2.19%)
EVFM : 4.00 (+2.56%)
INCY : 78.42 (-0.32%)
AMGN : 203.88 (+0.97%)
ADRO : 2.70 (-6.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 198.33
1st Resistance Point 196.52
Last Price 194.70
1st Support Level 191.15
2nd Support Level 187.59

See More

52-Week High 194.92
Last Price 194.70
Fibonacci 61.8% 175.50
Fibonacci 50% 169.49
Fibonacci 38.2% 163.49
52-Week Low 144.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar